Drug Repurposing and Advanced Delivery Systems Targeting Multidrug-Resistant Microorganisms: A Narrative Review

Clicks: 9
ID: 337797
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #216 of 219 articles by views in Journal of applied microbiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 219 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Antimicrobial resistance (AMR) is a major global health threat, driven by the spread of multidrug-resistant (MDR) pathogens alongside a declining antibiotic pipeline. Drug repurposing offers a cost-effective, time-efficient alternative by identifying antimicrobial applications for approved drugs with established safety profiles. Agents including auranofin, niclosamide, gallium compounds, phenothiazines, selective serotonin reuptake inhibitors, ticagrelor, and dronedarone show antimicrobial, antibiofilm, antivirulence, and resistance-modifying activity through mechanisms distinct from conventional antibiotics, potentially limiting cross-resistance. However, reported in vitro minimum inhibitory concentrations (MICs) frequently exceed clinical breakpoints and plasma concentrations achievable at approved doses, confining most candidates to adjuvant or local therapy rather than systemic monotherapy. Poor solubility, limited bioavailability, unfavorable pharmacokinetics, and systemic toxicity further constrain clinical translation. Advanced drug delivery systems (DDS) like nanoparticles, liposomes, metal-organic frameworks, and stimuli-responsive carriers may mitigate these barriers by improving stability, targeting, infection-site accumulation, and controlled release. Such platforms can additionally enhance biofilm penetration, enable intracellular delivery, and permit co-delivery with conventional antibiotics to achieve synergy. Integrating repurposed agents with advanced DDS could therefore address key resistance mechanisms, including biofilm formation, efflux activity, and intracellular persistence, although substantial challenges remain despite encouraging preclinical data. This review critically evaluates the antimicrobial potential of repurposed non-antimicrobial drugs spanning anti-arthritic, anthelmintic, antineoplastic, psychiatric, and cardiovascular classes, examining mechanisms of action, efficacy evidence, and principal limitations, and assesses how advanced DDS might improve their therapeutic performance against MDR infections. It further identifies major evidence gaps and research priorities to guide development of clinically viable anti-AMR strategies.
Reference Key
openalex_W7224445947 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Meer M. Abdulkarim, Fattah H. Fattah, Ahmed G. Hamasaeed, Khanda A Anwar, Shvan Luqman Ezzat, Ayman M Mustafa, Karokh K. Mohammed, Shvan H Mohammed, Zhiran F Mahmood, Rebar A. Mohammed, Piroz Rahim Hama, Fahmi H. Kakamad
Are you one of these authors? Claim your profile
Journal Journal of applied microbiology
Year 2026
DOI
10.1093/jambio/lxag268
URL
https://doi.org/10.1093/jambio/lxag268
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.